Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: Report no. 1

Archives of Ophthalmology

Volumn 130, Issue 9, 2012, Pages 1127-1134

  Sohn, Elliott H ^a,b   He, Shikun ^b,c   Kim, Leo A ^b,d   Salehi Had, Hani ^b   Javaheri, Michael ^b   Spee, Christine ^b,c   Dustin, Laurie ^b   Hinton, David R ^b,c   Eliott, Dean ^b,d  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CONNECTIVE TISSUE GROWTH FACTOR; VASCULOTROPIN;

ADULT; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE SEVERITY; EYE; FEMALE; HUMAN; MALE; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PREOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINA DETACHMENT; TRACTION RETINAL DETACHMENT; VASCULARIZATION; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; AQUEOUS HUMOR; CONNECTIVE TISSUE GROWTH FACTOR; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL DETACHMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; VITREOUS BODY;

EID: 84866068097     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2012.1611     Document Type: Article

References (47)

1. Eliott D, Lee MS, Abrams GW. Proliferative diabetic retinopathy: principles and techniques of surgical treatment. In: Ryan SJ, ed. Retina. 4th ed. St Louis, MO: Elsevier Mosby; 2006:2413-2449.
2. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13(1):37-50. (Pubitemid 27213792)
3. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331(22):1480-1487. (Pubitemid 24356306)
4. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445-450. (Pubitemid 24307211)
5. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams GW. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122(3):393-403. (Pubitemid 26300056)
6. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38(1):36-47. (Pubitemid 27051522)
7. Saika S, Yamanaka O, Sumioka T, et al. Fibrotic disorders in the eye: targets of gene therapy. Prog Retin Eye Res. 2008;27(2):177-196.
8. He S, Chen Y, Khankan R, et al. Connective tissue growth factor as a mediator of intraocular fibrosis. Invest Ophthalmol Vis Sci. 2008;49(9):4078-4088.
9. Kuiper EJ, de Smet MD, van Meurs JC, et al. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol. 2006;124(10):1457-1462. (Pubitemid 44537147)
10. βRII. Invest Ophthalmol Vis Sci. 2011;52(8):5068-5078.
11. Hinton DR, He S, Jin ML, Barron E, Ryan SJ. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond). 2002;16(4):422-428. (Pubitemid 34845970)
12. terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care. 2004;27(3):758-764.
13. Abu El-Asrar AM, Van den Steen PE, Al-Amro SA, Missotten L, Opdenakker G, Geboes K. Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders. Int Ophthalmol. 2007;27(1):11-22. (Pubitemid 46672141)
14. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213-216. (Pubitemid 351224097)
15. Kuiper EJ, Van Nieuwenhoven FA, de Smet MD, et al. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. PLoS One. 2008;3(7):e2675. doi:10.1371/journal.pone.0002675.
16. Van Geest RJ, Lesnik-Oberstein SY, Tan HS, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol. 2012;96(4):587-590.
17. Sohn E. Bimanual vitreoretinal surgery for tractional retinal detachment due to proliferative diabetic retinopathy. Retina Today. 2011:42-44. http://bmctoday.net/retina360/2011/08/article.asp?f=retina-pearls-bimanual- vitreoretinal-surgery-for-tractional-retinal-detachment-due-to-proliferative- diabetic-retinopathy. Accessed August 6, 2012.
18. Han DP, Pulido JS, Mieler WF, Johnson MW. Vitrectomy for proliferative diabetic retinopathy with severe equatorial fibrovascular proliferation. Am J Ophthalmol. 1995;119(5):563-570.
19. Arimura N, Otsuka H, Yamakiri K, et al. Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology. 2009;116(5):921-926.
20. Hattori T, Shimada H, Nakashizuka H, Mizutani Y, Mori R, Yuzawa M. Dose of intravitreal bevacizumab (Avastin) used as preoperative adjunct therapy for proliferative diabetic retinopathy. Retina. 2010;30(5):761-764.
21. Qian J, Lu Q, Tao Y, Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina. 2011;31(1):161-168.
22. Sawada O, Kawamura H, Kakinoki M, Sawada T, Ohji M. Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol. 2007;125(10):1363-1366. (Pubitemid 47606601)
23. Matsuyama K, Ogata N, Jo N, Shima C, Matsuoka M, Matsumura M. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab. Jpn J Ophthalmol. 2009;53(3):243-248.
24. Forooghian F, Kertes PJ, Eng KT, Agrón E, Chew EY. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci. 2010;51(5):2388-2392.
25. Yamaji H, Shiraga F, Shiragami C, Nomoto H, Fujita T, Fukuda K. Reduction in dose of intravitreous bevacizumab before vitrectomy for proliferative diabetic retinopathy. Arch Ophthalmol. 2011;129(1):106-107.
26. Igarashi A, Okochi H, Bradham DM, Grotendorst GR. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell. 1993;4(6):637-645. (Pubitemid 23183611)
27. β action on fibroblasts. Cytokine Growth Factor Rev. 1997;8(3):171-179.
28. , endothelin-1 and CCN2 axis in scleroderma. Front Biosci (Elite Ed). June 1 2009;1:115-122.
29. Okada H, Kikuta T, Kobayashi T, et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J AmSoc Nephrol. 2005;16(1):133-143. (Pubitemid 43073165)
30. Uchio K, Graham M, Dean NM, Rosenbaum J, Desmoulière A. Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen. 2004;12(1):60-66. (Pubitemid 38249137)
31. Lang C, Sauter M, Szalay G, et al. Connective tissue growth factor: a crucial cytokine-mediating cardiac fibrosis in ongoing enterovirusmyocarditis. J Mol Med (Berl). 2008;86(1):49-60.
32. Kuiper EJ, Witmer AN, Klaassen I, Oliver N, Goldschmeding R, Schlingemann RO. Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. Br J Ophthalmol. 2004;88(8):1082-1087. (Pubitemid 39013155)
33. Suzuma K, Naruse K, Suzuma I, et al. Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Flt1, and phosphatidylinositol 3-kinase-akt-dependent pathways in retinal vascular cells. J Biol Chem. 2000;275(52):40725-40731. (Pubitemid 32054890)
34. β(2), elucidated by treatment with CTGFsiRNA. Acta Ophthalmol. 2010;88(6):652-659.
35. Inoki I, Shiomi T, Hashimoto G, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002;16(2):219-221.
36. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005;243(1):3-8.
37. Sharma RK, Rowe-Rendleman CL. Validation of molecular and genomic biomarkers of retinal drug efficacy: use of ocular fluid sampling to evaluate VEGF. Neurochem Res. 2011;36(4):655-667.
38. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695-1705.e6. doi:10.1016/j.ophtha.2006.05.064.
39. Mason JO III, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(4):685-688. (Pubitemid 44442055)
40. Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009;116(10):1943-1948.
41. Lo WR, Kim SJ, Aaberg TMSr, et al. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (Avastin). Retina. 2009;29(7):926-931.
42. Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A,Miniaci S, Williams G. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008;246(6):837-842.
43. di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):785-791.
44. Yeoh J, Williams C, Allen P, et al. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Experiment Ophthalmol. 2008;36(5):449-454.
45. Ahn J, Woo SJ, Chung H, Park KH. The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy. Ophthalmology. 2011;118(11):2218-2226.
46. Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2011;(5):CD008214.
47. Brigstock DR, Steffen CL, Kim GY, Vegunta RK, Diehl JR, Harding PA. Purification and characterization of novel heparin-binding growth factors in uterine secretory fluids: identification as heparin-regulated Mr 10,000 forms of connective tissue growth factor. J Biol Chem. 1997;272(32):20275-20282. (Pubitemid 27340141)